Miruvor
Sign up
The short answer

What studies of Escitalopram (Lexapro) found

12papers on Escitalopram (Lexapro)
153people in 4 studies testing Escitalopram (Lexapro) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty), for depression.

2 outcomes rated · see each below

Preventing long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 3 findings, all C.

3 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, Escitalopram (Lexapro) might help some people, but research can’t show it yet. For preventing long COVID, Escitalopram (Lexapro) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 12 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Escitalopram (Lexapro) · Long COVID is hereEscitalopram (Lexapro) · Preventing long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Depression2 studies · 69 people took Escitalopram (Lexapro) Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); helped less than vortioxetine, an active treatment; not a sign of harm.

Compared with another group, not randomised140 in the study · over 8 weeks · 10-20 mg/d

Depression improved less than with the comparison treatment.

Escitalopram (Lexapro) helped depression less than vortioxetine in the one comparison. Uncertain · very low certainty –

  • Serious risk of bias (ROBINS-I)
  • Helped less than vortioxetine, an active treatment; not a sign of harm

Studies with no comparison group33 in the study · for 10 weeks · 10 mg per day (20 in cases of severe depression)

Depression improved.

The evidence is very uncertain about the effect of escitalopram (Lexapro) on depression in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (33 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome: Real-World Evidence. (2025)

    People in the study
    140 in the study
    Dose
    10-20 mg/d
    Outcome
    Montgomery-Asberg Depression Rating Scale (MADRS) Montgomery-Asberg Depression Rating Scale
    Effect
    worse
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  2. P.0370 Escitalopram efficacy in post-covid depression treatment: a pilot study (2021)

    People in the study
    33 in the study
    Dose
    10 mg per day (20 in cases of severe depression)
    Outcome
    Hamilton Depression Scale score after 10-week treatment 17-item Hamilton Depression Scale
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 36 people took Escitalopram (Lexapro) Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); helped less than vortioxetine, an active treatment; not a sign of harm.

Compared with another group, not randomised140 in the study · over 8 weeks · 10-20 mg/d

Cognition (brain fog) improved less than with the comparison treatment.

Escitalopram (Lexapro) helped cognition (brain fog) less than vortioxetine in the one comparison. Uncertain · very low certainty –

  • Serious risk of bias (ROBINS-I)
  • Helped less than vortioxetine, an active treatment; not a sign of harm
See the 1 study
  1. Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome: Real-World Evidence. (2025)

    People in the study
    140 in the study
    Dose
    10-20 mg/d
    Outcome
    Digital Symbol Substitution Test (DSST) Digital Symbol Substitution Test
    Effect
    worse
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome

Preventing long COVID

Symptoms

Depression2 studies · 84 people took Escitalopram (Lexapro) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).

Studies with no comparison group2 studies · 84 people with results

Depression improved.

The evidence is very uncertain about the effect of escitalopram (Lexapro) on depression later, when given during acute COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 2 studies
  1. THERAPY OF POST-COVID DEPRESSION: A PROACTIVE PSYCHOSOMATIC APPROACH. (2023)

    People in the study
    44 in the study · 42 with outcome data
    Dose
    5 mg per day for the first week and 10 mg per day for 2–8 weeks for the initial level of mild to moderate depression; 10 mg per day for the first week and 20 mg per day for 2–8 weeks for severe initial levels of depression
    Outcome
    Depression Severity Level on the Hamilton Depression Scale (HAM-D) Hamilton Depression Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Proactive psychosomatic approach to the post-COVID depression treatment (2021)

    People in the study
    44 in the study · 42 with outcome data
    Dose
    5 мг на день протягом першого тижня та 10 мг на день протягом 2-8 тижнів, при початковому рівні депресії від легкого до середнього
    Outcome
    HADS-D mean change Госпітальна шкала тривоги та депресії (субшкала депресії, HADS-D)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety2 studies · 84 people took Escitalopram (Lexapro) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance; only people who finished were analysed.

Studies with no comparison group2 studies · 84 people with results

Low mood or anxiety improved.

The evidence is very uncertain about the effect of escitalopram (Lexapro) on low mood or anxiety later, when given during acute COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • Only people who finished were analysed
See the 2 studies
  1. THERAPY OF POST-COVID DEPRESSION: A PROACTIVE PSYCHOSOMATIC APPROACH. (2023)

    People in the study
    44 in the study · 42 with outcome data
    Dose
    5 mg per day for the first week and 10 mg per day for 2–8 weeks for the initial level of mild to moderate depression; 10 mg per day for the first week and 20 mg per day for 2–8 weeks for severe initial levels of depression
    Outcome
    Depression severity level on the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) Hospital Anxiety and Depression Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Proactive psychosomatic approach to the post-COVID depression treatment (2021)

    People in the study
    44 in the study · 42 with outcome data
    Dose
    5 мг на день протягом першого тижня та 10 мг на день протягом 2-8 тижнів, при початковому рівні депресії від легкого до середнього
    Outcome
    Ефективність есциталопраму у зменшенні симптомів депресії
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Quality of life2 studies · 84 people took Escitalopram (Lexapro) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).

Studies with no comparison group2 studies · 84 people with results

Quality of life improved.

The evidence is very uncertain about the effect of escitalopram (Lexapro) on quality of life later, when given during acute COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 2 studies
  1. THERAPY OF POST-COVID DEPRESSION: A PROACTIVE PSYCHOSOMATIC APPROACH. (2023)

    People in the study
    44 in the study · 42 with outcome data
    Dose
    5 mg per day for the first week and 10 mg per day for 2–8 weeks for the initial level of mild to moderate depression; 10 mg per day for the first week and 20 mg per day for 2–8 weeks for severe initial levels of depression
    Outcome
    Quality of Life Scale by A.S. Chaban (CQLS) Quality of Life Scale by A.S. Chaban
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Proactive psychosomatic approach to the post-COVID depression treatment (2021)

    People in the study
    44 in the study · 42 with outcome data
    Dose
    5 мг на день протягом першого тижня та 10 мг на день протягом 2-8 тижнів, при початковому рівні депресії від легкого до середнього
    Outcome
    CQLS mean change Шкала якості життя Чабана О.С. (CQLS)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Studies of combinations

Outcomes that only studies of Escitalopram (Lexapro) given together with other treatments looked at. Shown, not graded: they can’t tell what Escitalopram (Lexapro) did alone.

Daily functioning Both together

Combination: Physical therapy / physiotherapy + Cycling + Jogging and running + Salt, electrolytes and fluids + Compression garments + Fludrocortisone / Florinef + Midodrine + Atenolol (Tenormin) + Mestinon / pyridostigmine + Ivabradine + Clonidine + Methylphenidate (Ritalin, Concerta) + Fexofenadine (Allegra) + Famotidine (Pepcid) + Cromolyn (Gastrocrom, Nalcrom) + Baicalein and quercetin + Escitalopram (Lexapro) + Low-dose naltrexone1 in the study

A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023): activity tolerance competing in cross country event, better (not tested).

Shown, not counted: Escitalopram (Lexapro) was given together with other treatments.

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    5 to 10 mg at the start in most studies

  2. 2Raise

    Raised step by step in 1 of 4 studies

  3. 3Top dose

    Most often 5 mg (2 of 4 studies)

Doses across 4 studies

5 to 10 mg. One study of 140 people went up to 20 mg.

Each study’s dose, as printed

All papers

  1. Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome: Real-World Evidence.2025 · compared with another group · 140 in the study
    Summary

    This prospective, open-label comparative study was carried out at 1 clinical site in people with post-COVID syndrome and new-onset major depressive disorder. A total of 140 participants were assigned to receive vortioxetine (n = 70), escitalopram (n = 36), or sertraline (n = 34) over 8 weeks. Vortioxetine was given at 10-20 mg/d, escitalopram at 10-20 mg/d, and sertraline at 50-200 mg/d. The primary outcome was change from baseline to end point in the Digital Symbol Substitution Test (DSST); secondary outcomes were change in the Montgomery-Asberg Depression Rating Scale (MADRS) and the Patient Reported Outcome Measurement Information System Fatigue Short Form 7a (PROMIS 7a). For DSST, participants assigned to vortioxetine showed significant changes from baseline to end point compared with escitalopram (least squares [LS] mean difference 8.25; 95% CI 6.25-10.25; P < .001) and sertraline (LS mean difference 8.00; 95% CI 5.95-10.06; P < .001). For total MADRS, the vortioxetine group showed significantly greater changes than escitalopram (LS mean difference -4.06; 95% CI -4.92 to -3.20; P < .001) and sertraline (LS mean difference -3.94; 95% CI -4.83 to -3.06; P < .001). Side effects, withdrawals, worsening, and the number analysed were not reported in the abstract. The authors state that vortioxetine has a significant procognitive effect and that antidepressant effects and improvement in fatigue symptoms (PROMIS 7a) also were observed. No limitations are stated in the abstract.

  2. SSRI Use During Acute COVID-19 Infection Associated with Lower Risk of Long COVID Among Patients with Depression2024 · compared with another group · 506,903 with outcome data · preprint
  3. SSRI use during acute COVID-19 and risk of long COVID among patients with depression.2024 · compared with another group · 302,626 with outcome data
    Summary

    This retrospective cohort used N3C electronic health records from patients with a depressive disorder and acute SARS-CoV-2 infection. The text reports 302,626 patients; 100,803 (33%) were SSRI users and 201,823 (67%) were nonusers. Table 1 lists 101,016 SSRI users and 202,354 nonusers. SSRI use was defined as beginning at least 30 days before COVID-19 and continuing through acute COVID-19. SSRI users were compared with all other patients, defined as nonusers. The outcome was Long COVID (PASC) diagnosis by ICD code U09.9 between 1 and 12 months (day 31 to 365) after acute infection. SSRI users had a lower risk of Long COVID than nonusers (adjusted risk ratio 0.922, 95% CI 0.863 to 0.986). The unadjusted association was 1.042 (95% CI 0.984 to 1.104). New SSRI users also had a lower risk (adjusted risk ratio 0.886, 95% CI 0.780 to 0.985). For fluoxetine, sertraline, escitalopram, paroxetine, and citalopram, the study did not detect an association with Long COVID. No dose-response was found for fluoxetine 60 mg vs 10 mg (adjusted risk ratio 1.421, 95% CI 0.656 to 3.080). Harms, withdrawals, and people who worsened were not reported. The authors state limitations include binary time-invariant exposure, possible outcome misclassification, residual bias from observational design, and limited generalizability.

  4. THERAPY OF POST-COVID DEPRESSION: A PROACTIVE PSYCHOSOMATIC APPROACH.2023 · no comparison group · 44 in the study · 42 with outcome data
    Summary

    This single-arm study, conducted at Bogomolets National Medical University in Kyiv, Ukraine, asked whether early 8-week escitalopram monotherapy would reduce post-COVID depression. Hospitalized patients with coronavirus disease were screened; 44 patients with post-COVID depression were involved, and 42 completed the study. Two patients left the study early, and their data were not included in final processing. Escitalopram was given for 8 weeks: 5 mg per day for the first week and 10 mg per day for 2–8 weeks for initial mild to moderate depression, or 10 mg per day for the first week and 20 mg per day for 2–8 weeks for severe initial depression. There was no comparison group. Outcomes included HADS-D, HAM-D, SSS-8 and CQLS. From baseline to week 8, HADS-D changed from 15.00 to 7.09 (t –14.09, p<0.001), HAM-D from 21.26 to 7.04 (t –24.85, p<0.001), SSS-8 from 6.90 to 4.52 (t 5.37, p<0.001), and CQLS from 58.23 to 69.54 (t 4.58, p<0.001). At the end of the 8th week, 24 (57.14%) had no signs of depression on HAM-D and 18 had subclinical manifestations; the reported effectiveness of escitalopram in reducing depressive symptoms was 66%. Side effects were not reported.

  5. P.0370 Escitalopram efficacy in post-covid depression treatment: a pilot study2021 · no comparison group · 33 in the study
    Summary

    This pilot study assessed escitalopram in 33 patients after COVID-19 who had depressive symptoms arising in the recovery period. Patients were assessed at Railway Clinical Hospital #1 and the Department of Medical Psychology, Psychosomatic Medicine and Psychotherapy of National Medical University. The intervention was escitalopram 10 mg per day (20 mg in cases of severe depression) added to standard therapy of post-COVID syndrome for 10 weeks. There was no comparison group and the study was not randomised. Depressive symptoms were measured with the 17-item Hamilton Depression Scale. The mean score was 15.57 ± 4.16 points before escitalopram prescription and 5.72 ± 2.87 points after 10-week treatment. The reported decrease from baseline was 9.84 ± 4.63 points (p<0,001). After treatment, 21 participants had no symptoms of depression (63,64%), 10 participants (30,30%) had mild depression and 1 participant (3,03%) had moderate depression. The authors state the effect did not depend on age or gender. Harms and withdrawals were not reported. The authors note that persistence of the effect was not evaluated and that further studies with more patients and a control group are promising.

  6. Proactive psychosomatic approach to the post-COVID depression treatment2021 · no comparison group · 44 in the study · 42 with outcome data
    Summary

    This study examined a proactive psychosomatic approach for post-COVID depression. Hospitalized patients with coronavirus disease were screened; 44 patients with post-COVID depression were enrolled, and 42 (95,5%) completed the study. Two (4,5%) withdrew early and their data were not included in the final analysis; reasons were not reported. Patients received escitalopram (Medopram, Medochemi Ltd) for 8 weeks. For mild-to-moderate baseline depression, the dose was 5 mg/day in the first week and 10 mg/day in weeks 2–8; for severe baseline depression, 10 mg/day in the first week and 20 mg/day in weeks 2–8. There was no comparison group. Outcomes were HADS-D, HAM-D, SSS-8 and CQLS, with HAM-D every 2 weeks. Among completers, HADS-D changed from 15.00 ± 3.09 to 7.09 ± 2.36 (t -14.09, p<0,001); HAM-D from 21.26 ± 3.59 to 7.04 ± 2.45 (t -24.85, p<0,001); SSS-8 from 6.90 ± 3.46 to 4.52 ± 2.72 (t 5.37, p<0,001); CQLS from 58.23 ±14.61 to 69.54 ±10.61 (t 4.58, p<0,001). At 8 weeks, 24 (57,14%) had no depression signs by HAM-D and 18 (42,86%) had subclinical signs. The text reports 2 early withdrawals and does not report reasons or other side effects. The authors state that further study is needed in randomised controlled trials.

  7. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.2008 · no comparison group · 18 in the study · 16 started · 16 with outcome data
    Summary

    The authors hypothesized that s-citalopram therapy may improve the symptoms of both disorders in CFS patients with co-morbid depression. This open-label study enrolled 18 outpatients with chronic fatigue syndrome and co-morbid major depressive disorder; 16 received s-citalopram 10 mg to 20 mg daily for up to 12 weeks, with no comparison group. Outcomes included the Chalder Fatigue Questionnaire (CFQ), the multi-dimensional Fatigue Impact Scale (FIS), the CFS symptom rating (CFS-SR) 100 mm visual analogue scale, and CGI severity and change ratings for CFS, plus HAM-D, BDI and CGI ratings for depression. The paper reports reductions over time in mean CFQ score (p < 0.0005), FIS score (p < 0.0005), and CGI/S and CGI/C ratings of CFS (p < 0.0005). It reports a significant improvement in 5 of the 8 CFS-SR symptoms; the text names post-exertion malaise (p = 0.001), headaches (p < 0.0005), un-refreshing sleep (p < 0.0005), and impaired memory and concentration (p < 0.0005), while Table 1 also prints muscle pain with p = 0.001. The text states no significant change over time in lymph node tenderness, sore throat, or multiple joint pain. HAM-D, BDI and CGI ratings of MDD also fell. Five patients (31.3%) discontinued treatment prior to study completion for lack of efficacy. The most frequently occurring adverse events were daytime tiredness, gastrointestinal upset, jitteriness, diminished libido, insomnia, and agitation; the majority were rated as ‘mild’ or ‘moderate’ in severity.

  8. Alleviation of Post-COVID-19 Cognitive Deficits by Treatment with EGb 761®: A Case Series.2022 · case report · 5 in the study
    Summary

    This case series describes 5 outpatients with post-COVID-19 cognitive deficits after SARS-CoV-2 infection between December 2020 and July 2021. Patients received 2 x 80 mg EGb 761® daily, with observation up to 6 months; there was no comparison group. Cognitive deficits were rated with CGIS and CGIC, and neuropsychological performance with MoCA. During EGb 761® treatment, 3 patients experienced a partial remission of post-COVID-19 cognitive impairment (CGIC 5), while 2 showed a nearly complete remission of all cognitive symptoms (CGIC 1). None of the patients had any adverse effects of EGb 761® treatment. MoCA changed in individual patients: patient 4 improved by 4 points to 28, patient 1 improved from 29 to 30, patient 3 was reported as increasing to 30 in the case report but as MoCA 29 at follow-up in Table 2, and patient 2 remained at 30. Fatigue, concentration, olfaction and neuropsychiatric symptoms were also reported improved in individual patients. The authors state that a case series cannot show which aspects of recovery came from the pharmacologic effects of EGb 761®.

  9. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.2023 · combination: given with other treatments · 1 in the study
    Summary

    This case study reports a 19-year-old male who developed impairment consistent with ME/CFS after SARS-CoV-2 infection. The study reports one patient; there was no comparison group, and outcomes were before-versus-after over 30 months. Treatment included physical therapy; stationary biking and running as graded activity; oral sodium chloride and lower limb compression garments; and medications/supplements: fludrocortisone, midodrine, atenolol, pyridostigmine bromide, ivabradine, clonidine, methylphenidate, fexofenadine, famotidine, cromolyn, quercetin, escitalopram, and naltrexone. The paper reports significant improvement in symptoms over 30 months. With cromolyn, peak walking heart rate fell from the 130–140 bpm range to 100–105 bpm. Stopping fexofenadine and famotidine was accompanied on more than one occasion by increased fatigue and cognitive dysfunction; stopping H1 and H2 antihistamines was associated with worsened concentration and short-term memory. Naltrexone was associated with improved energy and overall function, and the patient reported improvements with low doses of clonidine and methylphenidate. For the first 15 months after infection, he continued to have exercise intolerance, with heart rate reaching 130–150 bpm during each of two 15-min walks daily. At one year, remaining symptoms included daily fatigue; lightheadedness and headaches were infrequent. He later resumed running at 10 min four times a week, increased running by two minutes each week, and in October 2022 competed in an 8 K event. Adverse effects were reported with fludrocortisone, midodrine, atenolol, pyridostigmine bromide, and ivabradine. Limitations stated include possible spontaneous improvement and uncertainty about independent effects of interventions.

  10. Late onset and persistent parosmia and dysgeusia as neurosensorial complication by the SARS virus COV 2.2023 · combination: given with other treatments · 1 in the study
    Summary

    This case report described one 25-year-old female with delayed and prolonged post-COVID parosmia and dysgeusia; the authors presented their treatment experience. There was no comparison group. Treatments included prednisone 0.5 mg/kg for 8 days, nasal irrigation with saline solution three times a day for 10 days plus Mupirocin for 10 days, Gabapentin 300 mg orally every 8 hours for 1 month, Escitalopram 5 mg daily, multivitamins, and olfactory rehabilitation. A transfusion of 50 million mesenchymal stem cells of endometrial origin showed no evidence of improvement even 8 weeks after it. The first COVID-19 vaccine dose was followed by an improvement of 25% of the parosmia and dysgeusia in the 7 days after application. After the second dose, an olfactory test found 40%, compared with 2 of 16 odors (12%) identified earlier. The report described mild improvement with prednisone, gabapentin, nasal irrigations and olfactory rehabilitation, greater after the second vaccine dose; improvement in depression but minimal improvement in parosmia and dysgeusia. Harms and withdrawals were not reported. Follow-up was 12 months after suffering the condition, when parosmia and dysgeusia still persisted.

  11. The potential therapeutic approaches targeting gut health in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a narrative review.2025 · review
    Summary

    This narrative review searched English peer-reviewed literature from January 1995 to January 2025 via PubMed, Scopus, and Web of Science to synthesize data on gut microbiota, inflammatory markers, and therapeutic outcomes in ME/CFS. The review did not report enrolling patients. It describes probiotic studies: an Italian pilot 8-week course improved well-being and reduced inflammation; in 15 ME/CFS patients, three strains improved neurocognitive function but no significant fatigue or physical activity reduction in only nine patients; Bifidobacterium infantis 35,624 in 48 patients lowered CRP, TNF-α, and IL-6. A 12-week Ubiquinol-10 randomized trial reported no significant fatigue improvement but reduced night-time awakenings; a 16-week randomized placebo-controlled trial of oral melatonin (1 mg) and zinc (10 mg) in 50 patients showed reductions in physical fatigue and improved quality of life. FMT: a retrospective study of 60 patients reported 70% response after four weeks and 58% maintained resolution for 15–20 years; another reported 17 of 21 patients with at least 60% improvement; a randomized placebo-controlled pilot in 11 patients (5 universal donor, 6 autologous) found no notable quality-of-life differences at 1 and 6 months. A Norway survey reported about 80% declined after graded exercise therapy; structured moderate activity over 12 to 26 weeks reduced fatigue compared with conventional/passive therapies; after a maximal exercise test, pain, fatigue, and confusion changed, with Clostridium in blood at 15 min and Bacilli increased at 48 h. Authors state current research lacks comprehensive insights and studies often produce conflicting findings, with varied diagnostic criteria and small samples.

  12. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
    Summary

    This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime